Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphobla.

The article outlines a phase II clinical trial, NCT06738368, evaluating the effectiveness of DA-EPOCH with or without rituximab plus JZP458 in treating newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. The trial involves a combination of chemotherapy drugs, anti-inflammatory drugs, and monoclonal antibodies to target cancer cells, with a focus on measurable residual disease negativity, adverse events, event-free survival, relapse-free survival, and overall survival. Led by primary investigator Ryan D. Cassaday, MD, the study is scheduled to begin on June 1, 2025, with an enrollment goal of 30 participants and a completion date of June 30, 2028. [Extracted from the article]